View Post

Torque Announces Clinical Trial Collaboration with Merck

In Clinical Trials by Barbara Jacoby

Source: Torque From: prnewswire.com Phase 1/2 combination clinical trial evaluating Torque’s Deep IL-15 Primed T Cells (TRQ-1501) and KEYTRUDA® (pembrolizumab) for the treatment of multiple cancer indications Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that it has entered into a clinical trial collaboration agreement …

View Post

Pfizer, Germany’s Merck begin large ovarian cancer trial

In In The News by Barbara Jacoby

Published by Reuters From: foxnews.com Pfizer Inc and German drugmaker Merck KGaA on Wednesday said they had begun a late-stage trial of their immuno-oncology drug avelumab in combination with standard treatment for ovarian cancer. The 950-patient study will enroll patients with advanced ovarian cancer who have not previously been treated for the disease, which is diagnosed annually in almost 23,000 …

View Post

Partnerships Play a Key Role in Developing Improved Ovarian Cancer Treatments

In In The News by Barbara Jacoby

Merck and ImmunoGen’s ovarian cancer partnership could help unlock potential of combining novel immune-oncology (IO) and non-IO drugs AstraZeneca and EMD Serono/Pfizer among other leading pharma firms championing IO and non-IO combination therapy in ovarian cancer, says analyst The recent announcement that Merck and ImmunoGen will partner to investigate a combination of their respective drugs, Keytruda and mirvetuximab soravtansine, for …

Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent

In In The News by Barbara Jacoby

By: Peter Loftus From: wsj.com Bristol-Myers Squibb Co. BMY -0.83% and partner Ono Pharmaceutical Co. 4528.TO -0.43% have sued Merck & Co. MRK -0.92% , alleging that its new cancer drug violates their patent for a method of harnessing the body’s immune system to fight cancer. Bristol and Ono filed suit in federal court in Delaware on Thursday, the same …

Immune Therapy’s Cancer Promise Creates Research Rush

In In The News by Barbara Jacoby

By: Naomi Kresge and Robert Langreth From: bloomberg.com A new class of medicines that help the body’s own immune cells fight tumors could target a wide set of cancers, opening a $35 billion market for Merck (MRK) & Co., Bristol-Myers Squibb Co., AstraZeneca Plc and Roche (ROG) Holding AG. The drugmakers will use the world’s largest meeting of cancer doctors, …